Study guide
3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence
Key Takeaways Explain This Topic AI
In premenopausal women, greater than 90% of adnexal masses are benign functional cysts (follicular or corpus luteum) that resolve spontaneously within 1 to 2 menstrual cycles.
Ovarian torsion is a surgical emergency requiring prompt diagnostic laparoscopy with detorsion; normal color Doppler arterial flow does not exclude torsion due to dual arterial perfusion.
Pelvic organ prolapse is objectively staged using the POP-Q system from Stage 0 to Stage IV, with conservative management centered on pelvic floor muscle training and supportive or space-occupying pessaries.
Urinary incontinence in women is primarily categorized into stress incontinence (urethral hypermobility/intrinsic sphincter deficiency) and urge incontinence (detrusor overactivity), requiring distinct behavioral, pharmacologic, and surgical treatments.
Last updated: October 2026
Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence
Important
Normal arterial flow on color Doppler ultrasound does not rule out ovarian torsion. In up to 30% to 50% of surgically confirmed torsion cases, dual arterial supply from the ovarian and uterine arteries preserves detectable Doppler flow. When clinical history and examination suggest torsion, emergent surgical exploration must not be delayed based on normal Doppler findings.
Benign Adnexal Masses
Adnexal masses are common clinical findings across the female lifespan, but their differential diagnosis and management differ fundamentally between premenopausal and postmenopausal individuals. In premenopausal patients, greater than 90% of adnexal masses are benign, whereas postmenopausal masses carry a substantially higher risk of malignancy, requiring risk stratification via serum CA-125, the Risk of Ovarian Malignancy Algorithm (ROMA), or multimodal ultrasound criteria (e.g., IOTA simple rules).
Adnexal Mass Type Etiology & Pathophysiology Sonographic Characteristics Clinical Management
Follicular Cyst Failure of dominant mature Graafian follicle to rupture or ovulate Thin-walled, unilocular, smooth margins, anechoic fluid, posterior acoustic enhancement; typically 3 to 8 cm Expectant management; spontaneous resolution within 1 to 2 menstrual cycles (6–8 weeks)
Corpus Luteum Cyst Failure of corpus luteum to regress after ovulation; fills with fluid or blood Thick-walled, complex unilocular cyst with internal reticular "lace-like" cobwebs; peripheral "ring of fire" vascular flow Expectant management; follow-up ultrasound if symptomatic; monitor for rupture/hemoperitoneum
Mature Cystic Teratoma (Dermoid) Benign germ cell tumor composed of all three germ cell layers (sebaceous fluid, hair, calcifications) Focal hyperechoic nodule (Rokitansky protuberance/dermoid plug), acoustic shadowing ("tip-of-the-iceberg" sign), hyperechoic lines/dots Elective cystectomy due to 15% risk of torsion, secondary rupture, or chemical peritonitis
Endometrioma ("Chocolate Cyst") Localized invagination and accumulation of ectopic cyclic bleeding on ovarian surface Homogeneous, diffuse, low-level internal echogenicity ("ground-glass" appearance); lack of internal nodular vascularity Surgical cystectomy (preferred over drainage/cautery to minimize recurrence) or hormonal suppression
Ovarian Torsion: A Surgical Emergency
Ovarian torsion occurs when the ovary and often the fallopian tube twist around their vascular axis (the infundibulopelvic ligament and utero-ovarian ligament), obstructing venous and lymphatic outflow, causing massive stromal edema, and culminating in arterial thrombosis and ischemic necrosis.
Risk Factors : Adnexal masses 5 to 10 cm in diameter have the highest propensity to twist. Benign cystic teratomas and functional cysts are the most common culprits. Torsion rarely occurs with malignant or endometriotic masses due to dense adhesive fixation.
Clinical Presentation : Sudden-onset, severe, sharp, unilateral lower quadrant pelvic pain, frequently accompanied by waves of nausea and vomiting (>70% of cases). A low-grade fever or leukocytosis may signify tissue necrosis.
Management : Emergent diagnostic laparoscopy is the gold standard. Current clinical standards dictate prompt laparoscopic detorsion with ovarian preservation, regardless of a dark or cyanotic appearance, as substantial follicular function recovers in the majority of conserved ovaries. Oophorectomy is reserved for overt gangrenous necrosis or postmenopausal women.
Pelvic Organ Prolapse (POP)
Pelvic organ prolapse (POP) involves the descent of one or more pelvic structures—the anterior vaginal wall, posterior vaginal wall, cervix/uterus, or vaginal apex—into or beyond the vaginal canal.
Anatomical Compartments
Anterior Compartment (Cystocele) : Herniation of the bladder base into the anterior vaginal wall, resulting from attenuation of the pubocervical fascia.
Posterior Compartment (Rectocele) : Protrusion of the anterior rectal wall into the posterior vagina due to defects in the rectovaginal septum.
Apical Compartment (Uterine Prolapse or Vaginal Vault Prolapse) : Descent of the cervix and uterus down the vaginal axis, or eversion of the vaginal apex (cuff) following prior hysterectomy.
Enterocele : Herniation of peritoneal small bowel loops through the pouch of Douglas into the upper posterior vaginal canal.
Risk Factors
Predisposing factors include vaginal parity (with risk rising steeply with operative forceps deliveries), advancing age, hypoestrogenism, elevated chronic intra-abdominal pressure (chronic cough, constipation with repetitive straining, heavy occupational lifting, obesity), and genetic connective tissue disorders (e.g., Ehlers-Danlos syndrome).
Staging Systems: Baden-Walker Versus POP-Q
While the older Baden-Walker Halfway System utilizes grades 0 through 4 based on subjective relation to the hymenal ring, modern evidence-based practice and board certification examinations rely on the Pelvic Organ Prolapse Quantification (POP-Q) system : POP-Q Staging Criteria (Points measured in cm relative to the hymen during maximum Valsalva):
- Stage 0: No prolapse; points Aa, Ap, Ba, Bp are -3 cm; C/D between -tvl and -(tvl-2 cm).
- Stage I: Most distal portion of the prolapse is >1 cm above the hymen (<-1 cm).
- Stage II: Most distal portion of prolapse is between 1 cm above and 1 cm below the hymen (-1 cm to +1 cm).
- Stage III: Most distal portion of prolapse is >1 cm below the hymen, but <(tvl - 2 cm).
- Stage IV: Complete eversion of the vaginal canal (procidentia); leading edge protrudes ≥(tvl - 2 cm).
Management of POP
Conservative Therapies :
Pelvic Floor Muscle Training (PFMT) : Supervised Kegel exercises strengthen the levator ani complex, highly effective for symptom reduction in Stages I and II.
Vaginal Pessaries : First-line non-surgical therapy across all prolapse stages. Support pessaries (Ring with support) are ideal for early stages and sexually active patients. Space-occupying pessaries (Gellhorn, Cube) are required for Stage III/IV prolapse or compromised perineal bodies.
Pessary Care : Periodic removal and cleaning are essential. In postmenopausal patients, concurrent low-dose topical vaginal estrogen cream should be prescribed to prevent mucosal erosion, ulceration, and bleeding.
Surgical Management : Reconstructive surgery (sacrocolpopexy, sacrospinous ligament fixation, colporrhaphy) restores anatomy, while obliterative surgery (colpocleisis) closes the vaginal lumen in patients who do not desire future coitus.
Urinary Incontinence (UI) in Women
Urinary incontinence is the involuntary loss of urine, categorized into distinct clinical phenotypes:
Stress Urinary Incontinence (SUI)
Mechanism : Involuntary leakage upon exertion, coughing, sneezing, laughing, or position change in the absence of a detrusor contraction. Etiologies include urethral hypermobility (insufficient pelvic floor and endopelvic fascial support permitting downward rotation of the bladder neck under abdominal pressure) and intrinsic sphincter deficiency (ISD) (loss of mucosal coaptation and intrinsic sphincter closure tone).
Evaluation : Visualized transurethral leak during an office Cough Stress Test; Q-tip test demonstrating resting-to-straining angle excursion >30 degrees (hypermobility). Post-void residual (PVR) is normal (<50–100 mL).
Management : PFMT (3 sets of 10–12 contractions daily for ≥3 months); continence pessaries (incontinence dish with knob); midurethral synthetic sling (tension-free vaginal tape [TVT] or transobturator tape [TOT]), which remains the surgical gold standard.
Urge Urinary Incontinence (UUI) & Overactive Bladder (OAB)
Mechanism : Involuntary leakage accompanied or immediately preceded by intense urgency, driven by uninhibited detrusor muscle contractions during bladder filling ( detrusor overactivity ). Overactive bladder syndrome consists of urgency, frequency (≥8 voids/24h), and nocturia (waking at night to void), with (OAB-wet) or without (OAB-dry) urge incontinence.
Management :
First-line : Behavioral therapy (scheduled voiding, bladder training intervals, urge suppression techniques, fluid management, avoiding caffeine/alcohol).
Second-line : Antimuscarinics (oxybutynin, tolterodine, solifenacin) block M2/M3 receptors; adverse effects include dry mouth, constipation, and cognitive impairment in older adults. Beta-3 adrenergic agonists (mirabegron 25–50 mg daily, vibegron 75 mg daily) stimulate detrusor relaxation without anticholinergic cognitive side effects; mirabegron requires blood pressure monitoring (contraindicated in severe uncontrolled hypertension BP ≥180/110 mmHg).
Third-line : Intravesical onabotulinumtoxinA injections, sacral neuromodulation (InterStim), or percutaneous tibial nerve stimulation (PTNS).
Mixed & Overflow Incontinence
Mixed Incontinence (MUI) : Concomitant stress and urge components; clinical management focuses on identifying and treating the most bothersome symptom first.
Overflow Incontinence : Continuous dribbling resulting from impaired detrusor contractility (diabetic neuropathy) or anatomical outlet obstruction (severe prolapse). Characterized by an elevated post-void residual volume (PVR >200–300 mL). Treatment involves clean intermittent catheterization (CIC) or relieving obstruction (pessary reduction); antimuscarinics are strictly contraindicated.